{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:47:16Z","timestamp":1791244036261,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00262-021-02851-5","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T13:03:43Z","timestamp":1611147823000},"page":"2197-2207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5729","authenticated-orcid":false,"given":"Sabrina","family":"Hoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Laaouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Al Jumaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Nevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Saltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Himmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rottapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Colmegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Fifi-Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliese","family":"Tisseverasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2851_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"2851_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","volume":"17","author":"LC Kennedy","year":"2019","unstructured":"Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw 17:750\u2013757","journal-title":"J Natl Compr Canc Netw"},{"key":"2851_CR3","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 71:2100\u20132111","journal-title":"Arthritis Rheumatol"},{"key":"2851_CR4","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M et al (2019) Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24:e327\u2013e337","journal-title":"Oncologist"},{"key":"2851_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905\u20131912","journal-title":"J Clin Oncol"},{"key":"2851_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376","journal-title":"Ann Oncol"},{"issue":"1","key":"2851_CR7","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/jitc-2020-000538","volume":"8","author":"N Martinez Chanza","year":"2020","unstructured":"Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B et al (2020) Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J Immunother Cancer 8(1):e000538","journal-title":"J Immunother Cancer"},{"key":"2851_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21\u201329","journal-title":"Eur J Cancer"},{"key":"2851_CR9","unstructured":"U.S. Department of Health and Human Sciences NIoH, (2020) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 [October 12, 2020]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"2851_CR10","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595","journal-title":"Autoimmun Rev"},{"key":"2851_CR11","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH Jr (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376:1989\u20131991","journal-title":"N Engl J Med"},{"key":"2851_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","volume":"29","author":"A Barbacki","year":"2018","unstructured":"Barbacki A, Maliha PG, Hudson M, Small D (2018) A case of severe Pembrolizumab-induced neutropenia. Anticancer Drugs 29:817\u2013819","journal-title":"Anticancer Drugs"},{"key":"2851_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N (2016) PD-1\/PD-L and autoimmunity: a growing relationship. Cell Immunol 310:27\u201341","journal-title":"Cell Immunol"},{"key":"2851_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.170544","volume":"45","author":"H Chen","year":"2018","unstructured":"Chen H, Peng Q, Yang H, Yin L, Shi J, Zhang Y et al (2018) Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis. J Rheumatol 45:835\u2013840","journal-title":"J Rheumatol"},{"key":"2851_CR15","doi-asserted-by":"publisher","first-page":"e0192704","DOI":"10.1371\/journal.pone.0192704","volume":"13","author":"Y Guo","year":"2018","unstructured":"Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X et al (2018) Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE 13:e0192704","journal-title":"PLoS ONE"},{"key":"2851_CR16","first-page":"2156","volume":"32","author":"M Kobayashi","year":"2005","unstructured":"Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y et al (2005) Enhanced expression of programmed death-1 (PD-1)\/PD-L1 in salivary glands of patients with Sj\u00f6gren\u2019s syndrome. J Rheumatol 32:2156\u20132163","journal-title":"J Rheumatol"},{"key":"2851_CR17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872\u20132878","journal-title":"J Clin Oncol"},{"key":"2851_CR18","doi-asserted-by":"publisher","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","volume":"4","author":"G Fuc\u00e0","year":"2019","unstructured":"Fuc\u00e0 G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4:e000457","journal-title":"ESMO Open"},{"key":"2851_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24:1259\u20131269","journal-title":"Oncologist"},{"key":"2851_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.19.01674","volume":"38","author":"H Abu-Sbeih","year":"2020","unstructured":"Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38:576\u2013583","journal-title":"J Clin Oncol"},{"key":"2851_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","volume":"57","author":"Y Nakanishi","year":"2019","unstructured":"Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T et al (2019) Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig 57:451\u2013459","journal-title":"Respir Investig"},{"key":"2851_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K et al (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9:847\u2013855","journal-title":"Thorac Cancer"},{"key":"2851_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S et al (2020) Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 69:15\u201322","journal-title":"Cancer Immunol Immunother"},{"key":"2851_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17:255\u201389","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02851-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T13:05:40Z","timestamp":1626699940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02851-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2851"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02851-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"17 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This submission represents original work that is not under consideration elsewhere and that has not been previously published. All authors participated in the preparation of the manuscript. All authors meet criteria for authorship and will sign a statement attesting authorship, disclosing all potential conflicts of interest and releasing the copyright should the manuscript be acceptable for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Patient consent was waived due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}